SBC Medical Group Holdings Incorporated (SBC)

Emerging Growth Research reiterated a Buy rating for SBC Medical Group (NASDAQ: SBC) and raised its price target to $11.00 following a strong Q2:26 performance. The company reported a 13% year-over-year revenue increase to $49.2 million and expects AI initiatives to contribute up to $15 million in additional annual revenue. SBC Medical also expanded its clinic network, maintained a strong cash position, and continues international growth, making it appear undervalued according to the firm's DCF analysis.

Emerging Growth Research has released its Q2:26 Quarterly Update Report on SBC Medical Group Holdings, reiterating a Buy rating and increasing the 12-month price target to $11.00 from $10.00. The report highlights SBC Medical Group's return to revenue growth, strong cash position, expanding clinic footprint, international expansion, and new AI-driven growth initiatives. Emerging Growth Research believes the company is undervalued given its long-term earnings potential and growth drivers.

Zacks Research has lowered its FY2026 earnings per share forecast for SBC Medical Group (NASDAQ:SBC) to $0.42, down from $0.49, which is below the analyst consensus of $0.48. This comes after SBC Medical Group reported quarterly EPS of $0.10, missing expectations, despite revenue of $49.19 million exceeding estimates. Analyst sentiment for the stock is mixed, with two "Buy" ratings and one "Sell" rating, and the company's shares opened at $3.68, with an average price target of $8.50.

SBC Medical (SBC) reported strong Q2 2026 earnings, with total revenue up 13% and net income attributable to SBC Medical increasing by 335% year-over-year. The company attributes this growth to structural reforms completed in 2025, expanded management services revenue, and growth in point business. SBC Medical is focusing on a multi-brand domestic strategy, international expansion, and integrating AI to improve operational efficiency and customer experience, aiming for 1,000 clinics by 2035.

SBC Medical Group Holdings Inc (SBC) reported strong Q2 2026 results, with adjusted EBITDA growing 32% year-over-year despite currency headwinds from a weaker yen. The company expanded its clinic network to 287 locations and saw significant organic growth in same-clinic revenue and average spend per visit. SBC is accelerating its aesthetic dermatology business with a multi-brand strategy, expanding into non-aesthetic healthcare, and leveraging AI for operational efficiency and customer experience, while also pursuing global expansion and aiming for normalized valuation in U.S. capital markets.